Ed Schoonveld examines the uncertainty surrounding President Trump's MFN drug pricing agreements, stalled GENEROUS, GLOBE and GUARD proposals, and their ripple effects on ex-US drug launches.
Commentary|Podcasts|June 21, 2024
Navigating Market Access Hurdles
Mark Bouck discusses PharmAlliance’s latest acquisitions, while reiterating its goals surrounding health economics and outcomes research.
Advertisement
In this exclusive PC Podcast interview, Mark Bouck, chairman and CEO of PharmAlliance, a pharmaceutical and life sciences services platform, dives into:
- How PharmAlliance’s acquisition of Complete Health Economics Outcomes Research Solutions (CHEORS) helps expand global reach
- The platform’s biggest goal to when it comes to CHEORS and market access services
- How CHEORS helps navigate cost-effectiveness and market access hurdles
- Acquisitions in the space that are currently in the works
The latest episode of The Pharmaceutical Commerce Podcast is available directly on
Advertisement
Related to this article
In this week's Pharma Pulse, nine more drugmakers join the MFN program, GoodRx adds a family plan, IPC formalizes its USave partnership, and CSafe expands its thermal cover offerings.
Rebate delays could force 340B hospitals to pay upfront and wait months for credit, distorting drug spend on the books. Valerie Bandy, PharmD, of Tecsys explains the fallout.
Go behind the scenes of LogiPharma USA 2026 with program director Charleen Ring and McKesson's Chris Van Norman in this Pharma Pulse special.
An FTC settlement moved one PBM aggregator onshore, but manufacturers still lack contract-level clarity on what affiliated fees actually buy.
As HRSA's 340B Rebate Model Pilot moves toward its effective date, Valerie Bandy, PharmD, of Tecsys explains what drug-by-drug rebate tracking really demands from hospital and health system pharmacies.
Pharma pricing shifts beyond PBM rebates as Medicare and cash channels reshape launches, WAC cuts and access strategies.
In this week's Pharma Pulse, DHL breaks ground on a new cold chain hub at Singapore's Changi Airport, a new report finds pharma's commercial model in the middle of a fundamental reset, and the FDA grants accelerated approval to sevabertinib.
Advertisement
Advertisement
Trending on Pharmaceutical Commerce
1
White House Extends MFN Pricing to Every State Medicaid Program
2
Pharma Pulse: Independent Pharmacies Sue Express Scripts, Novo Taps Anthropic, Pharma Joins Clean Heat
3
The PBM Entity No Pharmaceutical Company Directly Contracted With
4
How Rebate Timing Distorts a Pharmacy's 340B Books
5